ストックスクリーナーアプリを入手
34.99
1.16%
-0.41
Alkermes Plc (ALKS) 最新ニュース
Alkermes (ALKS) Q1 2026 Earnings Transcript - AOL.com
Alkermes plc 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ALKS) 2026-05-07 - Seeking Alpha
Alkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market - TipRanks
Alkermes price target raised to $48 from $42 at UBS - TipRanks
Alkermes price target raised to $50 from $45 at Needham - TipRanks
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises - MSN
Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results - Benzinga
Alkermes Q1 2026 earnings preview - MSN
Did Rising Revenue but New Net Loss Just Shift Alkermes' (ALKS) Investment Narrative? - Sahm
Alkermes plc (NASDAQ:ALKS) Q1 2026 Earnings Call Transcript - Insider Monkey
Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company (ALKS) - Seeking Alpha
Alkermes Q1 2026 slides: Avadel deal drives revenue beat By Investing.com - Investing.com Australia
Stifel raises Alkermes stock price target on orexin pipeline progress - Investing.com UK
Alkermes plc Q1 2026 10-Q: Financial Highlights, Risk Factors, and Forward-Looking Statements - Minichart
Stifel raises Alkermes stock price target on orexin pipeline progress By Investing.com - Investing.com Nigeria
Alkermes stock hits 52-week high at $36.48 By Investing.com - Investing.com South Africa
Alkermes Earnings Call: LUMRYZ Momentum Drives Growth - TipRanks
Alkermes plc reports first quarter 2026 financial results - MSN
Insider Sell: David Gaffin Sells Shares of Alkermes PLC - GuruFocus
Alkermes plc Q1 2026 Earnings Call Summary - Yahoo Finance
Avadel deal shifts Alkermes (NASDAQ: ALKS) to Q1 loss on higher costs - Stock Titan
Alkermes stock hits 52-week high at $36.48 - Investing.com
Alkermes Q1 2026 Earnings Call Transcript - MarketBeat
ALKS: Q1 2026 delivered robust sales growth, expanded sleep medicine presence, and advanced orexin pipeline - TradingView
Alkermes Q1 2026 slides: Avadel deal drives revenue beat - Investing.com
Alkermes plc Reports First Quarter 2026 Financial Results - BioSpace
Earnings call transcript: Alkermes Q1 2026 results beat expectations, stock rises - Investing.com
Alkermes Plc reports results for the quarter ended March 31Earnings Summary - TradingView
Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Alkermes Swings to Q1 Loss, Revenue Rises; Reiterates 2026 Revenue Guidance - marketscreener.com
Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo! Finance Canada
Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss - ChartMill
Alkermes rises as quarterly loss narrows, tops estimates By Investing.com - Investing.com Nigeria
Q1 2026 Alkermes Plc Earnings Call Transcript - GuruFocus
Alkermes rises as quarterly loss narrows, tops estimates - Investing.com
(ALKS) Alkermes Expects 2026 Revenue Range $1.73B$1.84B, vs. FactSet Est of $1.80B - marketscreener.com
Earnings Flash (ALKS) Alkermes Posts Q1 Net Loss $0.40 a Share, vs. FactSet Est of $0.58 Loss - marketscreener.com
Alkermes reports Q1 2026: Revenues $392.9M, GAAP loss $66.5M, Adjusted EBITDA $80.3M - TradingView
Alkermes: Q1 Earnings Snapshot - Barchart
Avadel deal drives Alkermes (NASDAQ: ALKS) Q1 growth and 2026 EBITDA upgrade - Stock Titan
Alkermes (ALKS) CLO David Gaffin sells 2,034 shares, retains 231,558 - Stock Titan
Insider sales reported for Alkermes (NASDAQ: ALKS) on Form 144 — three transactions listed - Stock Titan
1.49%
1.78%
大文字化:
|
ボリューム (24 時間):